04/06/2010 - SPARK Ventures to realise its investment in Complinet  |  06/05/2010 - CNBC launches on Livestation  |  17/12/2009 - Livestation adds CNN International to its channel offering  |  IMImobile raises $13m of equity for expansion  |  18/09/2009 - Founders of SPARK Ventures’ portfolio company notonthehighstreet.com win ‘Entrepreneur of the Year'  |  28/08/2009 - SPARK Ventures realises its investment in Unanimis  |  19/06/2009 - Telecom Express and IMImobile join forces to launch IMEXmobile - Mobile Interaction Specialist

Biological therapies:

Celldex Therapeutics, Inc.

GlycArt AG

Glycoform

Haemostatix

Oxford BioMedica plc

Oxitec

Diagnostics & point-of-care:

IDG

Oxford Biosensors

Oxford Immunotec

Vivacta Limited

Disease Management & wellness:

Gemini Biomedical

Genosis plc

Instrumentation:

Teraview

IT in Healthcare:

Mirada Solutions

Medical Devices & Medical Technology:

(No investments to date)

Nanotechnology:

Oxonica plc

Pharmaceuticals and Speciality pharmaceuticals:

Allergy Therapeutics plc

Cyclacel Inc

Lectus Therapeutics

Medigene AG

Oxagen

PowerMed

Sterix

Vernalis plc

Xention

Telemedicine & e-Health:

(No investments to date)

 

 

Sterix, a spin-out from the University of Bath and Imperial College, was sold to Ipsen Group, a European specialist pharmaceutical company, in 2004.

Sterix specializes in the research and development of a new generation of steroid-based therapeutic products for use in oncology and metabolism or endocrine-related diseases, including cancer treatments, women's health, diabetes and hormone-associated diseases. The acquisition allowed Ipsen to reinforce its pipeline in the field of oncology and build upon the innovative work carried out by Sterix.  

View website